There are currently 174 active clinical trials seeking participants for Heart Failure research studies. The states with the highest number of trials for Heart Failure participants are California, Florida, Texas and Pennsylvania.
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207
Recruiting
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +221 locations
Conditions: Heart Failure, Systemic Inflammation
Register for Updates
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
04/15/2025
Locations: Local Institution - 0002, Birmingham, Alabama +102 locations
Conditions: Heart Failure
Register for Updates
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
NCT06215586
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Cardurion Investigative Site, Birmingham, Alabama +75 locations
Conditions: Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Register for Updates
Pulmonary Artery Catheter in Cardiogenic Shock Trial
NCT05485376
Recruiting
The primary objective of the PACCS trial is to assess if early invasive hemodynamic assessment and ongoing management with a PAC in patients with cardiogenic shock due to acutely decompensated heart failure (AHDF-CS) is associated with lower in-hospital mortality risk compared to the current standard of care with no or delayed PAC assessment.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/14/2025
Locations: Tufts Medical Center, Boston, Massachusetts
Conditions: Cardiogenic Shock, Heart Failure
Register for Updates
A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)
NCT06215911
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Cardurion Investigative Site, Birmingham, Alabama +111 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases, Heart Diseases
Register for Updates
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR
NCT03142152
Recruiting
The objective of this prospective, randomized, blinded clinical trial is to assess the safety and efficacy of the Carillon Mitral Contour System in treating heart failure with functional regurgitation (FMR).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/10/2025
Locations: Dignity Health Research Institute at Mercy Gilbert and Chandler Regional Medical Centers, Gilbert, Arizona +68 locations
Conditions: Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases, Cardiovascular Diseases, Heart Valve Diseases
Register for Updates
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/09/2025
Locations: Research Site, Centreville, Alabama +770 locations
Conditions: Heart Failure
Register for Updates
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574
Recruiting
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/03/2025
Locations: Advanced Cardiovascular, LLC, Alexander City, Alabama +17 locations
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Register for Updates
Tailored Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients With Heart Failure
NCT06847438
Recruiting
Recent medical guidelines for the management of heart failure (HF) have established a combination of specific classes of medications as the best treatment for patients with heart failure with reduced ejection fraction (HFrEF). However, studies have shown that these medications, known together as guideline-directed medical therapy (GDMT), are not being used in clinical practice less often than they could be. Several tools to promote broader use of these treatments (including patient checklists) h... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Emory Saint Joseph's Hospital, Atlanta, Georgia +3 locations
Conditions: Heart Failure
Register for Updates
Promoting Well-being and Health in Heart Failure
NCT04829617
Recruiting
The focus of this study is to test the efficacy of a 12-week, phone-delivered Positive Psychology-Motivational Interviewing (PP-MI) intervention, with additional twice weekly PP and health behavior text messages for a total of 24 weeks (with interactive, algorithm-driven, goal-focused text messages in the final 12 weeks), compared to an attention-matched MI-based educational condition, in a randomized trial (NIH Stage II) of 280 patients with New York Heart Association class I-III Heart Failure... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Register for Updates
Evaluating the Reach of Clinical Decision Support for Patients With Heart Failure
NCT06847906
Recruiting
To work best, clinical decision support tools (CDS) must be timed to provide support when healthcare decisions are made, which includes virtual visits (phone or video). Unfortunately, most CDS tools are either missing from virtual visits or not designed for the unique context of virtual visits (e.g., availability of physical assessments and labs, different workflows), which could generate new inequities for patients more likely to use virtual visits. The objective of this study is to test the re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: UCHealth Primary Care and Cardiology Outpatient Clinics, Aurora, Colorado
Conditions: Decision Support Systems, Clinical, Heart Failure
Register for Updates
The Inorganic Nitrate and eXercise Performance in Heart Failure (iNIX-HF)
NCT05562167
Recruiting
The goals of this project are to determine the effectiveness of acute (2 hours after a single dose) and chronic (after 6 weeks of once-a-day dosing) KNO3 treatment (10mmol) vs. placebo on quadriceps muscle power and on aerobic exercise performance (V̇O2peak) in patients with HFrEF (left ventricular ejection fraction \<45%). The investigators hypothesize that both acute and chronic dosing of 10mmol of KNO3 will improve exercise performance in HFrEF. To test this hypothesis, the investors will per... Read More
Gender:
ALL
Ages:
Between 19 years and 79 years
Trial Updated:
04/02/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Heart Failure
Register for Updates